

JAMES C. LAI, MD

Addresses

Work:

Retina Consultants of Hawaii, Inc.
98-1079 Moanalua Road, Suite 470
Aiea, Hawaii 96701
808-487-8928

Retina Consultants of Hawaii, Inc.
321 N. Kuakini Street, Suite 307
Honolulu, HI 96817
808-523-6131

Retina Consultants of Hawaii, Inc.
98-1079 Moanalua Road, Suite 410
Aiea, Hawaii 96701
808-487-8928

Retina Consultants of Hawaii, Inc.
1401 S. Beretania Street, Suite 340
Honolulu, Hawaii 96814
808-204-0943

Education

- | | |
|------------|---|
| 2002- 2003 | Chief Resident, Assistant Chief of Service,
and Director of Ocular Trauma Service
Wilmer Ophthalmological Institute
Johns Hopkins Medical Institutions
Baltimore, MD |
| 2000-2002 | Vitreoretinal Fellowship
Duke University Eye Center
Durham, NC |
| 1997-2000 | Ophthalmology Residency Program
The Wilmer Ophthalmological Institute
Johns Hopkins Medical Institutions
Baltimore, MD |
| 1996-1997 | University of Hawaii Integrated Transitional Residency Program
Honolulu, HI |
| 1992-1996 | Doctor of Medicine
University of Michigan Medical School
Ann Arbor, MI <ul style="list-style-type: none">• Top 5 of the class• Dean's Award for Research Excellence• Graduated with Distinction in Research |

1993-1994 Howard Hughes Medical Institute-National Institutes of Health (HHMI-NIH)
Research Scholars Program
 • Laboratory of Immunology at the National Eye Institute, NIH
 • Preceptors: Drs. Igal Gery and Robert Nussenblatt

1988-1992 Bachelor of Science in Biomedical Sciences
University of Michigan, Ann Arbor, MI
 • 7-year Integrated Premedical-Medical (Inteflex) Program
 • GPA: 3.93/4.00, Graduated Summa Cum Laude

Board Certification American Board of Ophthalmology
October 28, 2001
American Board of Ophthalmology
Recertification 2012

Licensure Hawaii 14115 (active)
New York- 227432 (inactive)
Maryland- D0058707 (inactive)
North Carolina- 2000 00249 (inactive)
DEA- BL6695879

Professional Activities

2003-May 2007 Long Island and Queens Vitreoretinal Consultants
600 Northern Blvd., Suite 216
Great Neck, NY 11021

May 2007 – present Retina Consultants of Hawaii
98-1079 Moanalua Road, Suite 470
Aiea, Hawaii 96701

Retina Consultants of Hawaii
321 North Kuakini Street, Suite 307
Honolulu, HI 96817

The Retina Center at Pali Momi
98-1079 Moanalua Road, Suite 410
Aiea, Hawaii 96701

Retina Consultants of Hawaii
1401 S. Beretania Street, Suite 340
Honolulu, HI 96814

Jun 2008 – Apr 2011 Retina Consultants of Hawaii
1380 Lusitana Street, Suite 502
Honolulu, HI 96813

Apr 2011–Apr 2016 Retina Consultants of Hawaii
1380 Lusitana Street, Suite 506
Honolulu, HI 96813

Hospital Appointments:

7/03-2007	North Shore University Hospital at Syosset, Syosset, NY
7/03-2007	Queens Hospital Center, Jamaica, NY
8/03-2007	Long Island Jewish Hillside Medical Center, New Hyde Park, NY
5/07-present	Pali Momi Medical Center, Aiea, HI
5/07-present	Queens Medical Center, Honolulu, HI

Academic Positions

2017 – Present	Clinical Associate Professor Department of Surgery John A Burns School of Medicine, University of Hawaii
2009 – 2017	Clinical Assistant Professor Department of Surgery John A Burns School of Medicine, University of Hawaii
2006-2007	Clinical Assistant Professor Department of Ophthalmology NYU School of Medicine
2003-2007	Attending Surgeon Department of Ophthalmology Long Island Jewish/North Shore University
2002- 2003	Assistant Chief of Service and Director of Ocular Trauma Service Wilmer Ophthalmological Institute Johns Hopkins Medical Institutions
2000- 2002	Clinical Instructor Retina Division Duke University Eye Center

Honors and Awards

2009 – Present	Best Doctors in America
2005-2006	Teaching Attending of Year Long Island Jewish/North Shore University Department of Ophthalmology
2002	Hornaday Fellow Teaching Award Duke University Eye Center
2000	Awarded AOS-Knapp Ophthalmic Foundation Fellowship
2000	Selected as Ronald G. Michels Foundation Award recipient
2000	Selected as the Society of Heed Fellows Fellow

	(awarded to the top Heed Fellow in the nation)
2000	Awarded Heed Ophthalmic Foundation Fellowship
1999	Ronald G. Michels Resident Research Award The Wilmer Ophthalmological Institute
1998	ARVO Travel Grant
1996	Hewlett-Packard Award Presented to the top 5 graduates of the medical school class
1996	Dean's Award for Research Excellence Awarded to the 2 graduating students who made outstanding research contributions during their medical school career.
1994	Alpha Omega Alpha (selected in junior year)
1994-1996	HHMI-NIH Research Scholars Continued Medical Studies Fellowship This scholarship, valued at \$55,200, is awarded to the top Scholars who demonstrated both outstanding research abilities and the most potential for a career in academic medicine.
1992-1996	Joseph Collins Foundation Scholarship Awarded to one student from each medical school class based on their academic performance, interests in the arts and sciences, and record of community service.
1991	Phi Beta Kappa
1991-1992	Literature, Sciences and Arts Academic Scholarship
1991-1992	University of Michigan Merit Scholarship
1991-1992	Stanley Waltz Alumni Academic Scholarship
1989-1992	Designated Angell Scholar for academic excellence
1988-1992	Class Honors
1989	William Branstrom Freshman Prize for academic excellence
1988	Westinghouse Science Talent Search, Semi-Finalist
1988	Winner in NY State Energy Conservation Research Competition
1988	National Merit Scholarship Winner
1988	High School Valedictorian (class of 525)

Publications

1. **Lai JC**, Wawrousek EF, Lee RS, Chan CC, Whitcup SM, Gery I. Intraocular inflammation in transgenic mice expressing a foreign antigen in their lens. *Ocul Immunol Inflamm.* 1995; 3:59-62.
2. **Lai JC**, Wawrousek EF, Sipe JD, Whitcup SM, Gery I. Reduced susceptibility to IL-1 and endotoxin in transgenic mice expressing IL-1 in their lens. *Cytokine.* 1996; 8(4):288-293.
3. Whitcup SM, Rizzo LV, **Lai JC**, Hayashi S, Gazzinelli R, Chan CC. IL-12 inhibits endotoxin-induced inflammation in the eye. *Eur J Immunol.* 1996; 26(5):995-999.

4. Fukushima A, **Lai JC**, Chanaud NP, Shiloach J, Whitcup SM, Nussenblatt RB, Gery I. Permissive recognition of immunodominant determinants of the retinal S-antigen in different rat strains, primates and humans. *Int Immunol*. 1997; 9(1):169-177.
5. **Lai JC**, Johnson MW, Martonyi CL, Till GO. Complement-induced retinal arteriolar occlusions in the cat. *Retina*. 1997; 81(2):499-505.
6. Whitcup SM, Pleyer U, **Lai JC**, Lutz S, Mochizuki M, Chan CC. Topical liposome-encapsulated FK-506 for the treatment of endotoxin-induced uveitis. *Ocul Immunol Inflamm*. 1998; 6(1):51-56.
7. **Lai JC**, Fukushima A, Wawrousek EF, Lobanoff MC, Charukamnoetkanok P, Smith-Gill S, Lee RS, Egwuagu CE, Whitcup SM, Gery I. Immunotolerance against a foreign antigen transgenically expressed in the lens. *Invest Ophthalmol Vis Sci*. 1998; 39(11):2049-2057.
8. Hwang JM, Girkin CA, Perry JD, **Lai JC**, Miller NR, Hellmann DB. Bilateral ocular ischemic syndrome secondary to giant cell arteritis progressing despite steroid treatment. *Am J Ophthalmol*. 1999; 127(1):102-104.
9. **Lai JC**, Lobanoff MC, Fukushima A, Wawrousek EF, Chan CC, Whitcup SM, Gery I. Uveitis induced by lymphocytes sensitized against a transgenically expressed lens protein. *Invest Ophthalmol Vis Sci*. 1999; 40(11):2735-2739.
10. de Vos AF, Fukushima A, Lobanoff MC, Vistica BP, **Lai JC**, Grivel JC, Wawrousek EF, Whitcup SM, Gery I. Breakdown of tolerance to a neo-self antigen in double transgenic mice in which B cells present the antigen. *J. Immun.* 2000;164:4594-4600.
11. Margalit E, Fujii GY, **Lai JC**, Gupta P, Chen S, Shyu J, Piyathaisere DV, Weiland JD, de Juan E, Humayun MS. Bioadhesives for intraocular use. *Retina*. 2000; 20:469-477.
12. **Lai JC**, Fekrat S, Barron Y, Goldberg MF. Traumatic hyphema in children: risk factors for complications. *Arch Ophthalmol*. 2001; 119:64-70.
13. **Lai JC**, Lapolice DJ, Stinnett SS, Meyer CH, Arieu LM, Keller MA, Toth CA. Visual outcomes following macular translocation surgery with 360° peripheral retinectomy. *Arch Ophthalmol*. 2002; 120:1317-1324
14. Stout JE, **Lai JC**, Giner J, Hamilton CD. Reactivation of retinal toxoplasmosis despite evidence of immune response to highly active antiretroviral therapy. *Clinical Infectious Diseases*. 2002; 35:37-39.
15. Greenman H, **Lai JC**. Contemporary approaches to management of hyphema. *Contemporary Ophthalmology*. 2002; 1(19):1-6.
16. **Lai JC**, Stinnett SS, McCuen BW. Comparison of silicone oil vs. gas tamponade in the treatment of idiopathic full-thickness macular hole. *Ophthalmology*. 2003; 110(6):1170-4.
17. **Lai JC**, Stinnett SS, Jaffe GJ. B-scan ultrasonography for the detection of macular thickening. *Am J Ophthalmol*. 2003; 136(1):55-61
18. **Lai JC**, Postel EA, McCuen BW. Recovery of visual function after removal of chronic subfoveal perfluorocarbon liquid. *Retina*. 2003; 23(6):868-70

19. Lai MM, **Lai JC**, Lee WH, Huang JJ, Patel S, Ying HS, Melia M, Haller JA, Handa JT. Comparison of retrobulbar and sub-Tenon's capsule injection of local anesthetic in vitreoretinal surgery. *Ophthalmology*. 2005; 112(4):574-9.
20. BH Zwerling, **JC Lai**, VA Deramo, BJ Rosenblatt. Success of scleral buckle following failed pneumatic retinopexy for repair of rhegmatogenous retinal detachment. *Invest Ophthalmol Vis Sci*. 46 (Suppl). 2005.
21. **Lai JC** and Shakin J. Diagnostic and therapeutic challenges. *Retina*. 2005; 25(7):930-5.
22. Mruthyunjaya P, Wirostko WJ, Chandrashekhar R, Stinnett S, **Lai JC**, Deramo V, Tang J, Dev S, Postel EA, Connor TB, Fekrat S. Central retinal vein occlusion in patients treated with long-term warfarin sodium (Coumadin) for anticoagulation. *Retina*. 2006; 26(3):285-91.
23. Deramo VA, **Lai JC**, Fastenberg DM, Udell IJ. Acute endophthalmitis in eyes treated prophylactically with fourth-generation fluoroquinolone antibiotics. *Am J Ophthalmol*. 2006; 142(5):721-5.
24. Yoganathan P, Deramo VA, **Lai JC**, Tibrewala RK, Fastenberg DM. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. *Retina*. 2006; 26(9):994-98.
25. Jonisch J, **Lai JC**, Deramo VA, Flug AJ and Fastenberg DM. Increase incidence of sterile endophthalmitis following intravitreal preserved Triamcinolone actinide. *Br. J. Ophthalmol*. 2008; 92: 1051-1054.
26. Shaikh S, Davis JL, Yeung L, **Lai JC**. Diagnostic and therapeutic challenges. *Retina*. 2009 Mar; 29(3):409-12.
27. Kokame GT, Yeung L, **Lai JC**. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy. *Br J Ophthal*. 2010 Mar; 94(3): 297-301. Epub 2009 Sep 1.
28. Yeung L, Kokame GT, Brod TD, Lightman DA, **Lai JC**. Pneumatic retinopexy for retinal detachment associated with severe choroidal detachment. *Retina*. 2011 Jan; 31(1): 87-92.
29. Kokame GT, Yeung L, Teramoto K, **Lai JC**, Wee R. Polypoidal choroidal vasculopathy exudation and hemorrhage – results of ranibizumab therapy at one year. *Ophthalmologica* 2014;231(2):94-102.
30. Kokame GT, **Lai JC**, Wee R, Yanagihara R, Shantha JG, Ayabe J, Hirai K. Prospective clinical trial of intravitreal aflibercept injection for polypoidal choroidal vasculopathy with hemorrhage or exudation (EPIC trial). *BMC Ophthalmology*. 2016 Jul; 16(127): 1-10.
30. de Carlo T, Kokame GT, Shantha JG, **Lai JC**, Wee R. Spectral-Domain Optical Coherence Tomography Angiography for the Diagnosis and Evaluation of Polypoidal Choroidal Vasculopathy. *Ophthalmologica* 2017 Dec; doi: 10.1159/000481540
31. Kokame GT, deCarlo T, Kaneko KN, Lian R, **Lai JC**, Wee R. Sensitivity and Specificity of Detecting Polypoidal Choroidal Vasculopathy with En Face OCT and OCT Angiography. *Retina*. 2019 Jul;39(7):1343-1352. doi: 10.1097/IAE.0000000000002139.

Book Chapters

1. **Lai JC**, Wawrousek EF, Lee RS, Chan CC, Whitcup SM, Gery I. Analysis of peripheral tolerance to autologous antigens expressed in an immunologically privileged site. In: Nussenblatt RB, Whitcup SM, Caspi RR, Gery I (editors). *Advances in Ocular Immunology*. Amsterdam: Elsevier Publishers, 1994.
2. Wawrousek EF, **Lai JC**, Gery I, Chan CC. Progressive inflammatory disease and neovascularization in the eyes of interleukin-1 β (IL-1 β) transgenic mice. In: Nussenblatt RB, Whitcup SM, Caspi RR, Gery I (editors). *Advances in Ocular Immunology*. Amsterdam: Elsevier Publishers, 1994.
3. **Lai JC**, Cooney M. Photodynamic therapy. In: Dunn JP (editor). *Macular Disease*. In *International Ophthalmology Clinics*. Hagerstown: Lippincott Williams and Wilkins, 1999.

Book Reviews

1. **Lai JC**. The Massachusetts Eye and Ear Infirmary Illustrated Manual of Ophthalmology. [book review]. *Am J Ophthalmol*. 1998; 126(6):854.
2. **Lai JC**. Principles and Practice of Ophthalmology. Second Edition. Editors: Albert DM and Jakobiec FA. [book review]. *Am J Ophthalmol*. 2000; 129(5):699-700.

Selected Abstracts and Presentations

1. **JC Lai**, CC Chan, Q Lian, SM Whitcup. Treatment with corticosteroids and cyclosporine A inhibits the expression of adhesion molecules in experimental autoimmune uveitis. *Invest Ophthalmol Vis Sci*. 34 (Suppl): 1206, 1993.
2. **JC Lai**, CL Martonyi, MW Johnson. Experimental complement-induced retinal arteriolar occlusions in the cat. (Oral presentation at 1993 National Student Research Forum, Galveston, Tx)
3. **JC Lai**, EF Wawrousek, JD Sipe, SM Whitcup, CC Chan, I Gery. Ocular and systemic immunological profile of interleukin-1 β (IL-1 β) transgenic mice. *Invest Ophthalmol Vis Sci*. 35 (Suppl): 1988, 1994. (Oral presentation, 1994 ARVO meeting)
4. RC Walton, **JC Lai**, NP Chanaud, CC Chan, I Gery, SM Whitcup. Inhibition of experimental autoimmune uveitis by MDL 28,842. *Invest Ophthalmol Vis Sci*. 35 (Suppl): 1865, 1994.
5. **JC Lai**, BP Vistica, RK Maturi, BL Shirkey, Y Sasamoto, SM Whitcup, I Gery. In vitro induction of anergy in rat lymphocytes. *J. Cell Biochem*. 18D (Suppl): 446, 1994.
6. **JC Lai**, EF Wawrousek, A Fukushima, MC Lobanoff, SM Whitcup, SJ Smith-Gill, I Gery. Immunotolerance in transgenic mice expressing a foreign antigen in their lens. *Invest Ophthalmol Vis Sci*. 36 (Suppl): 929, 1995. (Oral presentation, 1995 ARVO meeting)
7. MC Lobanoff, **JC Lai**, EF Wawrousek, A Fukushima, RS Lee, CC Chan, SM Whitcup, I Gery. Cell-mediated lens-induced uveitis in transgenic mice: a novel experimental eye disease. *Invest Ophthalmol Vis Sci*. 36 (Suppl). 1995.

8. A Fukushima, **JC Lai**, J. Shiloach, Y. Guex-Crosier, SM Whitcup, RB Nussenblatt, I. Gery. Promiscuous epitopes of human S-antigen stimulate lymphocytes with different MHC restrictions. Invest Ophthalmol Vis Sci. 36 (Suppl). 1995.
9. **JC Lai**, S Fekrat, Y Barron, MF Goldberg. Traumatic hyphema in children: risk factors for complications. Invest Ophthalmol Vis Sci. 39 (Suppl): 4657, 1998.
10. **JC Lai**, P Mruthyunjaya, S Fekrat. Central retinal vein occlusion in patients on chronic Coumadin anticoagulation. 2002 ARVO meeting.
11. **JC Lai**. Update on Macular Degeneration. Invited speaker at the Annual Connecticut Society of Eye Physicians, 2005.
12. **JC Lai**. Comparison of retrobulbar and sub-tenon's injection of local anesthetic in vitreoretinal surgery. Oral presentation at 2004 Retina Society.
13. BH Zwerling, **JC Lai**, VA Deramo, BJ Rosenblatt. Success of scleral buckle following failed pneumatic retinopexy for repair of rhegmatogenous retinal detachment. Invest Ophthalmol Vis Sci. 46 (Suppl). 2005.
14. Kokame GT, Yeung L, **Lai JC**. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: 6-month results. Br. J of Ophthal. 2010 Mar; 94(3):297-301. *Epub 2009 Sep 1*
15. Yeung L, Kokame GT, Brod RD, Lightman DA, **Lai JC**. Pneumatic Retinopexy for retinal detachment associated with severe choroidal detachment. Retina. 2011 Jan;31(1):87-92.
16. **JC Lai**. High-dose ranibizumab for treatment of polypoidal choroidal vasculopathy (PEARL2). Poster presentation. Retina Society Annual Meeting. September 2016.
17. Kaneko KN, Kokame GT, Wee R, Choi SY, Chen JJ, **Lai JC**. The Presence of Collateral Vessels is a Useful Prognostic Sign in Patients with Retinal Vein Occlusions. Retina Society Annual Meeting. September 2018.

Editorial Board

Contemporary Ophthalmology, Assistant Editor, 2002-2003

Organizations

American Academy of Ophthalmology
 Association for Research in Vision and Ophthalmology
 American Society of Retina Specialists
 Retina Society
 Wilmer Resident Alumni Association
 Duke Resident Alumni Association

Reviewer

Retina
 Archives of Ophthalmology

Course Instructor

1. *Controversies in macular hole surgery*. Instructional course at the American Academy of Ophthalmology, Orlando, FL, 2002
2. *Visual outcomes following full macular translocation*. Duke Full Macular Translocation Course, Durham, NC, 2002

Research

1. Sub-Investigator, Posterior Juxtascleral Injections of Anecortave Acetate versus Visudyne in Patients with Subfoveal Exudative Age-Related Macular Degeneration Eligible for Initial Treatment with Photodynamic Therapy using Visudyne, Industry-Sponsored Study
2. Sub-Investigator, A Phase II Prospective, Randomized, Double-Masked, Sham-Controlled, Dose-Ranging, Multi-Center Trial to Assess the Effect of Pegaptanib Sodium on Foveal Thickening in Patients with Exudative Subfoveal Age-Related Macular Degeneration, Industry-Sponsored Study
3. Sub-Investigator, Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer) Given every 6 weeks for 54 weeks in patients with age-related Macular Degeneration, Industry-Sponsored Study
4. Sub-Investigator, FOCUS Study, Multiple-dose Intravitreal Injections of rhuFab V2 in Combination with Verteporfin Photodynamic Therapy in Subjects with Neovascular Age-Related Macular Degeneration, Industry-Sponsored Study
5. Sub-Investigator, MARINA, rhuFab V2 Phase III study for Minimally Classic CNV secondary to AMD, Hawaii Center, Industry-Sponsored Study
6. Sub-Investigator, A Phase 2, Multi-Center, Randomized, Masked, Controlled, Study of Squalamine Lactate for the Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration, Industry-Sponsored Study
7. Sub-Investigator, A Phase II, Randomized, Double-Masked, Controlled, Dose Comparison Study of Cand5 for Intravitreal Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated with Wet Age-Related Macular Degeneration, Industry-Sponsored Study
8. Principal Investigator, A Six-Month, Phase 3, Multi-Center, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of Dexamethasone Posterior Segment Drug Delivery System in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion, Industry-Sponsored Study
9. Sub-Investigator, Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension versus Sham Administration in Patients at Risk for Developing Sight-Threatening Choroidal Neovascularization Due to Exudative Age-Related Macular Degeneration
10. Sub-Investigator, HORIZON Study, Phase III Open-Label Extension Study to Evaluate the Safety and Tolerability of ranibizumab in subjects with subfoveal CNV secondary to AMD who have previously completed the treatment phase of a Genentech-Sponsored ranibizumab study, Hawaii Center, Industry-Sponsored Study
11. Sub-Investigator, Phase IV, Randomized, Active Controlled, Double-Masked study comparing the safety and efficacy of Intravitreal Macugen® given every 6 weeks plus sham PDT vs Macugen® given every 6 weeks plus Visudyne® PDT in subjects with predominantly classic subfoveal CNV secondary to AMD, Hawaii Center, Industry-Sponsored Study
12. Sub-Investigator, Phase II/III Randomized, Double-Masked study comparing the safety and efficacy of intravitreal Macugen® given as often as every 6 weeks for 3 years, to Sham Injections in subjects with DME involving the center of the macula, Industry-Sponsored Study
13. Sub-Investigator, SAILOR Study, Phase IIIb, Multicenter Study to Evaluate the Safety and Tolerability of ranibizumab in Naïve and Previously Treated Subjects with Choroidal

- Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD), Hawaii Center, Industry-Sponsored Study
14. Sub-Investigator, A Randomized, Double-Masked, Parallel Group, Multi-Center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 mcg/day and ASI-001B 0.2 mcg/day Fluocinolone Acetonide Intravitreal Inserts to Sham injection in Subjects with Diabetic Macular Edema, Industry-Sponsored Study
 15. Principal Investigator, A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in patients with Neovascular Age-Related Macular Degeneration, Industry-Sponsored Study
 16. Sub-Investigator, Phase I Ranibizumab for Polypoidal Choroidal Vasculopathy (PEARL Trial), Investigator Sponsored Trial. Funding and medication provided by a research grant from Genentech, Inc
 17. Sub-Investigator, DENALI Study, A 24-Month Randomized, Double-Masked, Controlled, Multicenter, Phase IIIB Study Assessing Safety and Efficacy of Verteporfin (Visudyne®) PDT Administered in Conjunction with Ranibizumab (Lucentis™) Versus Ranibizumab (Lucentis™) Monotherapy in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration, Hawaii Center, Industry-Sponsored Study
 18. Sub-Investigator, RISE Study, Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus. Hawaii Center, Industry-Sponsored Study
 19. Sub-Investigator, Asian AMD Gene Study. Sponsored by a grant from the Hawaii Community Foundation
 20. Sub-Investigator, VIEW1 Study, A Randomized, Double-Masked, Active Controlled Phase III Study of the Efficacy, Safety and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration. Hawaii Center, Industry-Sponsored Study.
 21. Principal Investigator, POSURDEX Study, A 52-Week, Masked, Multicenter, Randomized, Controlled Trial (with Up to 13 weeks Additional Follow-Up) to Assess the Safety and Efficacy of 700ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in Combination with Laser Photocoagulation Compared with Laser Photocoagulation Alone in the Treatment of Subjects with Diffuse Diabetic Macular Edema (DME), Hawaii Center, Industry-Sponsored Study.
 22. Sub-Investigator, COBALT Study, A Phase III, randomized, double-masked, parallel-assignment study of intravitreal bevasiranib sodium, administered every 8 or 12 weeks as maintenance therapy following three injections of Lucentis compared with Lucentis monotherapy every 4 weeks in patients with Exudative Age-Related Macular Degeneration (AMD), Industry-Sponsored Study
 23. Sub-Investigator, DEGAS study, A Phase II Prospective, Randomized, Multi-Center, Dose Ranging, Comparator Study Evaluating the Efficacy and Safety of PF-04523655 Versus Laser in subjects with Diabetic Macular Edema, Industry-Sponsored Study
 24. Sub-Investigator, QUARK Study, A Phase I Open-Label, Dose Escalation Trial of REDD14NP Delivered by a Single Intravitreal Injection to Patients with Choroidal Neovascularization (CNV) Secondary to Exudative Age-Related Macular Degeneration, Industry Sponsored Study
 25. Sub-Investigator, PEARL2 Study, A Phase II Open Label, Investigator Sponsored Trial Evaluating High Dose Ranibizumab (2.0mg) in patients with Polypoidal Choroidal Vasculopathy (PCV) with Exudation and Bleeding, Investigator Sponsored study
 26. Principal Investigator, A Retrospective Data Collection Study in Patients Receiving Two or More OZURDEX (Dexamethasone Intravitreal Implant) 0.7 mg injections for Retinal Vein Occlusion, Industry-Sponsored Study
 27. Sub-Investigator, HARBOR Study, A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5mg and 2.0 mg ranibizumab

- administered monthly or on an as-needed basis (PRN) in patients with subfoveal neovascular age-related macular degeneration, Industry Sponsored Study
28. Sub-Investigator, DIAMOND Study, A Phase III, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injections of Sirolimus in Patients with Diabetic Macular Edema Secondary to Diabetic Retinopathy, Industry Sponsored Study
 29. Sub-Investigator, Time-Domain vs Spectral Domain OCT-Comparison Study, Diabetic Clinical Research Network
 30. Sub-Investigator, Multicenter, Randomized, Double-Masked, Placebo-Controlled, Dose-Escalation, Multiple-Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACU-4429 in Subjects with Dry Age-Related Macular Degeneration (Geographic Atrophy), Industry Sponsored Study
 31. Sub-Investigator, A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema, Industry Sponsored Study
 32. Sub-Investigator, iDEAL Study, A Randomized, Multi-Centered, Phase II Study of the Safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination with Ranibizumab of Laser Photocoagulation in the Treatment of Diabetic Macular Edema with Involvement of the Foveal Center, Industry Sponsored Study
 33. Sub-Investigator, CHROMA study, A Double-Masked, Randomized, Multi-Centered, Phase II study for Lampalizumab versus Sham for Geographic Atrophy and Dry AMD, Industry Sponsored Study
 34. Sub-Investigator, PALM Study, A Double-Masked, Randomized, Multi-Centered, Phase II study of Abicipar Pegol for Diabetic Macular Edema vs. Ranibizumab, Industry Sponsored Study
 35. Sub-Investigator, ORBIT study, a Phase IV study for safety and clinical outcomes of Ocriplasmin for Vitreomacular Traction, Industry Sponsored Study
 36. Sub-Investigator, EPIC study, An Open-Label study for Aflibercept for Polypoidal Choroidal Vasculopathy, Investigator Sponsored Study
 37. Sub-Investigator, VAPOR study, A randomized, multi-center, open-label, Phase IIa study for DE-120 and one treatment of aflibercept for Wet Macular Degeneration, Industry Sponsored Study.
 38. Sub-Investigator, HAWK study, A randomized, multi-center, double-masked Phase III study for RTH258 vs. aflibercept for Wet Macular Degeneration, Industry Sponsored Study
 39. Sub-Investigator, PALADIN study, A Phase IV study for follow up on clinical outcomes of Illuvien for DME, Industry Sponsored Study
 40. Principal Investigator, CEDAR study, A randomized, multi-center, double-masked Phase III study for Abicipar Pegol vs. ranibizumab for Wet Macular Degeneration, Industry Sponsored Study.
 41. Sub-Investigator, LHA510 study, A randomized, multi-center, double-masked Phase II study for topically delivered LHA510 for maintenance therapy for treated Wet Macular Degeneration, Industry Sponsored Study
 42. Sub-Investigator, Argus II Post Approval Study, A follow up study for the Argus II retinal prosthesis system, Industry Sponsored Study
 43. Sub-Investigator, Investigator, MAKO study, A Phase III study of the efficacy and safety of squalamine lactate ophthalmic solution, 0.2% twice daily in subjects with neovascular age-related macular degeneration, Industry Sponsored Study
 44. Sub-Investigator, ONYX study, A randomized, double masked, active-controlled phase 2 study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in patients with neovascular age-related macular degeneration, Industry Sponsored Study
 45. Sub-Investigator, RUBY study, A randomized, double-masked, active-controlled, phase 2 study of the efficacy, safety, and tolerability of repeated doses of intravitreal REGN910-3 in patients with diabetic macular edema, Industry Sponsored Study

46. Sub-Investigator, OMASPECT Study, Open-label extension study to evaluate the long-term safety and tolerability of lampalizumab in patients with geographic atrophy secondary to age-related macular degeneration
47. Primary Unmasked Investigator, SAPPHIRE Study, A randomized, masked controlled, phase 3 study of the safety and efficacy of Suprachoroidal CLS-TA with intravitreal aflibercept in patients with retinal vein occlusion
48. Sub-Investigator, SMD-201601, Study to determine the safety and tolerability of the SMD-DA system concomitant with anti-VEGF for patient with neovascular age-related macular degeneration, Industry Sponsored Study
49. Sub-Investigator, SB11-G31-AMD, Study to compare the efficacy, safety, pharmacokinetics and immunogenicity between SB11 and Lucentis in subjects with neovascular age-related macular degeneration, Industry Sponsored Study
50. Sub-Investigator, TOPAZ Study, A randomized, masked controlled, phase 3 study of the safety and efficacy of Suprachoroidal CLS-TA with intravitreal ranibizumab or bevacizumab in patients with retinal vein occlusion, Industry Sponsored Study
51. Sub-Investigator, OPH2003, A Phase IIb randomized, double masked controlled trials to assess the safety and efficacy of intravitreal administration of Zimura in subjects with geographic atrophy secondary to Dry AMD, Industry Sponsored Study
52. Sub-Investigator, YOSEMITE Study, A phase 3, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema, Industry Sponsored Study
53. Sub-Investigator, MERLIN Study, A multicenter, randomized, double-masked Phase 3a study to assess safety and efficacy of brolucizumab 6mg dose q4 weeks compared to q8 weeks in high anti-VEGF-need patients with wet AMD, Industry Sponsored Study
54. Sub-Investigator, KESTRE Study L, A phase 3, Randomized, multicenter, double-masked study assessing the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to diabetic macular edema, Industry Sponsored Study
55. Sub-Investigator, LUCERNE Study, A phase 3, multicenter, randomized, double-masked active comparator-controlled study to evaluate the efficacy and safety of faricimab in patients with neovascular AMD, Industry Sponsored Study
56. Sub-Investigator, PANDA Study, A two-year, four-arm, randomized, double-masked multicenter, phase 3 study assessing the efficacy and safety of brolucizumab versus aflibercept in adult patients with visual impairment due to diabetic macular edema, Industry Sponsored Study
57. Primary Investigator, ALTISSIMO Study, A phase 2b, multicenter, dose-ranging study evaluating the safety and efficacy of a long-acting intravitreal sunitinib malate depot formulation (GB-102) compared to intravitreal aflibercept in patients with neovascular AMD, Industry Sponsored Study
58. Sub-Investigator, KINGFISHER Study, A phase 3, two-arm, randomized, double-masked multicenter study assessing the efficacy and safety of brolucizumab every 4 weeks versus aflibercept every 4 weeks for patients with visual impairment due to diabetic macular edema, Industry Sponsored Study
59. Sub-Investigator, GATHER2 Study, A phase 3, multicenter, randomized, double-masked, sham-controlled clinical trial to assess the safety and efficacy of intravitreal administration of Zimura (complement C5 inhibitor) in patients with geographic atrophy secondary to dry AMD, Industry Sponsored Study
60. Sub-Investigator, RHONE-X Study, A multicenter, open-label extension study to evaluate the long-term safety and tolerability of faricimab in patients with diabetic macular edema, Industry Sponsored Study
61. Principal Investigator, CLKA651X2202 Study, A randomized, active-controlled, patient and investigator-masked, multiple dose proof-of-concept study of intravitreal LKA651 in patients with diabetic macular edema, Industry Sponsored Study

62. Sub-Investigator, PULSAR Study, A randomized, double-masked, active-controlled, phase 3 study of the efficacy and safety of high dose aflibercept in patients with treatment naïve wet AMD, Industry Sponsored Study
63. Sub-Investigator, PHOTON Study, A randomized, double-masked, active-controlled, phase 3 study of the efficacy and safety of high dose aflibercept in patients with diabetic macular edema, Industry Sponsored Study
64. Sub-Investigator, PAVILION Study, A phase 3, multicenter, randomized study of the efficacy, safety, and pharmacokinetics of the port deliver system with ranibizumab in patients with diabetic retinopathy, Industry Sponsored Study
65. Principal Investigator, BALATON Study, A phase 3, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of faricimab in patients with macular edema secondary to branch retinal vein occlusion, Industry Sponsored Study
66. Principal Investigator, COMINO Study, A phase 3, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of faricimab in patients with macular edema secondary to central of hemi retinal vein occlusion, Industry Sponsored Study
67. Sub-Investigator, GLIMMER Study, A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema, Industry Sponsored Study
68. Sub-Investigator, ATMOSPHERE Study, A Randomized, Partially Masked, controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD, Industry Sponsored Study
69. Sub-Investigator, AVONELLE-X Study, A multicenter, open-label extension study to evaluate the long-term safety and tolerability of faricimab in patients with neovascular AMD, Industry Sponsored Study
70. Sub-Investigator, DREAM Study, OTT166-201 A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy, Industry Sponsored Study
71. Sub-Investigator, LUNA Study, A multi-center, randomized, double-masked phase 2 study to assess safety and efficacy of ADV-022 (aav.7m8-aflibercept) in anti-VEGF treatment-experienced patients with nAMD, Industry Sponsored Study
72. Sub-Investigator, GATHER 2 OLE Study, An open-label extension (OLE) phase 3 trial to assess the safety of intravitreal administration of avacincaptad pegol in patients with geographic atrophy who previously completed phase 3 study ISEE2008, Industry Sponsored Study
73. Sub-Investigator, ASCENT Study, A Randomized, Partially Masked, controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD, Industry Sponsored Study
74. Sub-Investigator, DAVIO2 Study, A phase 2, multicenter, prospective, randomized, double-masked, parallel study of EYP-1901, a tyrosine kinase inhibitor (TKI), compared to aflibercept in subjects with nAMD, Industry Sponsored Study